ARX788 in Breast Cancer With Low Expression of HER2

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

NCT05331326 ·Status: UNKNOWN ·Phase: PHASE2

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

NCT05824325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

NCT03255070 ·Status: COMPLETED ·Phase: PHASE1

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

NCT06609187 ·Status: RECRUITING ·Phase: PHASE1

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

NCT05041972 ·Status: WITHDRAWN ·Phase: PHASE2

B002 in Patients With HER2-positive Breast Cancer

NCT04382352 ·Status: COMPLETED ·Phase: PHASE1

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

NCT05134519 ·Status: UNKNOWN ·Phase: PHASE2

Study of TFX06 in Women With Advanced Breast Cancer.

NCT05927779 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

NCT05165225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

NCT05489679 ·Status: TERMINATED ·Phase: PHASE1

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

NCT04296370 ·Status: UNKNOWN ·Phase: PHASE3

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

NCT06877416 ·Status: RECRUITING

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

NCT07294508 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

NCT04355858 ·Status: UNKNOWN ·Phase: PHASE2

Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

NCT06869174 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NCT06293898 ·Status: RECRUITING ·Phase: PHASE1

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

NCT03500380 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

NCT07187752 ·Status: NOT_YET_RECRUITING ·Phase: NA

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

NCT05263869 ·Status: UNKNOWN ·Phase: PHASE2

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

NCT06795503 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

NCT07002177 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

NCT06255392 ·Status: RECRUITING ·Phase: PHASE3